168893-40-1

Basic information

• Product Name: 5-(4-Amino-phenyl)-2H-[1,2,4]triazol-3-ylamine
• Synonyms: 5-(4-Amino-phenyl)-2H-[1,2,4]triazol-3-ylamine
• CAS NO: 168893-40-1
• Molecular Weight: 175.193
• Mol File: 168893-40-1.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 5-(4-Amino-phenyl)-2H-[1,2,4]triazol-3-ylamine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(4-Amino-phenyl)-2H-[1,2,4]triazol-3-ylamine(168893-40-1)
• EPA Substance Registry System: 5-(4-Amino-phenyl)-2H-[1,2,4]triazol-3-ylamine(168893-40-1)

Safety Data

• Hazardous Substances Data: 168893-40-1(Hazardous Substances Data)

Upstream product

• 636-97-5 N-amino-(4-nitrophenyl)carboxamide 
• 3679-93-4 4-Nitrobenzoic acid 2-amidinohydrazide 
• 59301-21-2 3-(4-nitrophenyl)-1H-1,2,4-triazol-5-amine 

Relevant articles and documents

Synthesis and pharmacological activity of triazole derivatives inhibiting eosinophilia

In order to develop novel antiasthmatic agents based on a new mechanism of action, a series of 3-substituted 5-amino-1- [(methylamino)(thiocarbonyl)]-1H-1,2,4-triazole derivatives were synthesized and evaluated in a model in which eosinophilia was induced in the airway through intravenous (iv) injection of Sephadex particles on days 0, 2, and 5. After screening of several hundred derivatives, we finally identified the highly potent eosinophilia inhibitor 5-amino-3-(4-chlorophenyl)-1- [(methylamino)(thiocarbonyl)]-1H-triazole (23c, GCC-AP0341), which had ID50 values of 0.3 and 0.07 mg/kg when administered orally (os) and intraperitoneally (ip), respectively. This compound showed complete inhibition of the hypersensitivity induced by ascaris inhalation at an ip dose of 1 mg/kg as well as low toxicity, with an LD50 value of >2.0 g/kg in mice. Extensive study of its mechanism of action revealed that 23c inhibited eosinophil survival induced by interleukin-5 (IL-5), but had little or no effect on leukotriene D4 (LTD4) or platelet-activating factor (PAF)- induced responses. Taken together, these results suggest 23c as a novel candidate for the treatment of chronic asthma. Further studies are now underway.